Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity By 2030 With The 1St Approved Bsadc By 2028 - Clinical Trials, Regulatory Approvals, Development Platforms.

New therapies like T-cell engagers and antibody-drug conjugates are showing survival gains in pretreated small cell lung ...

Improved Linker and Payload Selection: The selection of suitable linkers and cytotoxic payloads greatly impacts ADC stability, efficacy, and safety. Next-generation ADCs aim to employ novel linkers ...

Water-soluble polymers conjugated to proteins and anticancer drugs are in routine clinical use and clinical development as both single agents and components of combination therapy. This is ...

Please provide your email address to receive an email when new articles are posted on . The most common ocular adverse events with antibody-drug conjugates involve the ocular surface. The mainstay of ...

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky. The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates ...

Driving Innovation in Discovery and Chemistry, Validating Clinical Proof-of Concept and Streamlining CMC of Conjugates with Novel Payloads and Formats Traditional ADCs have seen significant success in ...

Infectious diseases remain a major health threat, as demonstrated by the emergence of COVID-19, which to date, is responsible for more than one million deaths globally. The ongoing evolution of viral ...

Antibody drug conjugates offer a niche opportunity in drug development and contract manufacturing. Targeted therapies such as monocolonal antibodies are an important part of anticancer drug ...

The 3rd Next-Generation Conjugates Summit (Boston | February 26-28, 2024) is the only event dedicated to showcasing conjugate drugs with novel payloads and formats, providing unrivalled access to 30+ ...